A study of fostamatinib in subjects with impaired kidney function

Study identifier:D4300C00009

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects with Renal Impairment Compared to Healthy Subjects following Administration of a Single Dose of Fostamatinib 150 mg

Medical condition

Rheumatoid Arthritis, Renal Impairment

Phase

Phase 1

Healthy volunteers

Yes

Study drug

fostamatinib

Sex

All

Actual Enrollment

24

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Jun 2011
Study Completion Date: 01 Jun 2011

Study design

Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Apr 2014 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria